Patrick G. Pilié, M.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The Univ. of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2011 | Duke University School of Medicine, Durham, NC, USA, MD, Medicine |
| 2006 | University of Georgia, Athens, GA, USA, BS, Genetics |
Postgraduate Training
| 2015-2018 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2011-2014 | Clinical Residency, Internal Medicine, University of Michigan, Ann Arbor, MI |
Board Certifications
| 2018 | American Board of Internal Medicine - Medical Oncology |
| 2014 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Hospitalist, Department of Hematology & SCT, University of Michigan, Ann Arbor, MI, 2014 - 2015
Other Appointments/Responsibilities
HHMI Medical Research Fellow, Duke University, Durham, NC, 2009 - 2010
Post-Baccalaureate Research Fellow, Duke University, Durham, NC, 2006 - 2007
Honors & Awards
| 2020 | ASCO Career Development Award, American Society of Clinical Oncology |
| 2019 | Young Investigator Award, Prostate Cancer Foundation |
| 2019 | Prostate Cancer SPORE Career Enhancement Award, The University of Texas MD Anderson Cancer Center |
| 2018 | Methods in Clinical Cancer Research Workshop, AACR/ASCO |
| 2018 | Young Investigator Award, Kidney Cancer Association |
| 2018 | Merit Award Recipient & Rapid-fire Oral Presentation, GU ASCO |
| 2017 | Loan Repayment Program Grant for Clinical Research, National Institute of Health |
| 2017 | Top Recipient for Fellows Research, Texas Society of Clinical Oncology |
| 2017 | Molecular Biology in Clinical Oncology Workshop, American Association of Cancer Research |
| 2014 | Plenary Oral Presentation Winner, University of Michigan IM Research Symposium |
| 2013 | Making A Difference Patient Care Award, University of Michigan |
| 2012 | Making A Difference Patient Care Award, University of Michigan |
| 2010 | Medical Student Research Grant, Howard Hughes Medical Institute |
| 2010 | Alpha-Omega-Alpha Research Award: Best Basic Science Presentation, Duke University |
| 2006 | Graduated Summa Cum Laude with research scholar distinction, University of Georgia |
| 2005 | Summer Undergraduate Research Program, New York University School of Medicine |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Wu C, Peng S, Pilié PG, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres-Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC. PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer. Mol Cancer Ther 20(9):1680-1691, 2021. e-Pub 2021. PMID: 34158347.
- Tang Z, Pilié PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC. ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer. Clin Cancer Res 27(17):4898-4909, 2021. e-Pub 2021. PMID: 34168048.
- Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, Pilie P, Sonbol MB, Alhalabi O. Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016. JAMA Netw Open 4(8):e2119568, 2021. e-Pub 2021. PMID: 34351403.
- McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661-672, 2021. e-Pub 2021. PMID: 33736924.
- Pilié PG, George A, Yap TA. Patient Selection Biomarker Strategies for PARP Inhibitor Therapy. Ann Oncol. e-Pub 2020. PMID: 33011228.
- Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 11(1):2135, 2020. e-Pub 2020. PMID: 32358509.
- Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37(5):720-734.e13, 2020. e-Pub 2020. PMID: 32359397.
- Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res 25(13):3759-3771, 2019. e-Pub 2019. PMID: 30760478.
- Pilie P, Jonasch E. Durable complete response in renal cell carcinoma clinical trials. Lancet 393(10189):2362-2364, 2019. PMID: 31079937.
- Pilié PG, Jonasch E. SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma. Oncotarget 10(16):1540-1541, 2019. e-Pub 2019. PMID: 30899419.
- Stewart RA, Pilié PG, Yap TA. Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Res 78(24):6717-6725, 2018. e-Pub 2018. PMID: 30498083.
- Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol 19(10):1351-1359, 2018. e-Pub 2018. PMID: 30236511.
- Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. e-Pub 2018. PMID: 30356138.
- Pilié PG, Cooney KA. Broadening the View of Germline Mutations in Kidney Cancer. JAMA Oncol 4(9):1235-1236, 2018. e-Pub 2018. PMID: 29978199.
- Pilié P, Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E. Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget 9(34):23390-23395, 2018. e-Pub 2018. PMID: 29805741.
- Pilié PG, LoRusso PM, Yap TA. Precision Medicine: Progress, Pitfalls, and Promises. Mol Cancer Ther 16(12):2641-2644, 2017. PMID: 29203693.
- Pilié PG, Johnson AM, Hanson KL, Dayno ME, Kapron AL, Stoffel EM, Cooney KA. Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer 123(20):3925-3932, 2017. e-Pub 2017. PMID: 28657667.
- Pilié PG, Jonasch E. Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. Kidney Cancer 1(1):57-64, 2017. e-Pub 2017. PMID: 30334005.
- Pilié PG, Jonasch E, McCutcheon IE. Key considerations in the treatment of von Hippel-Lindau disease. Future Oncol 12(15):1755-8, 2016. e-Pub 2016. PMID: 27020706.
- Pilie PG, Giri VN, Cooney KA. HOXB13 and other high penetrant genes for prostate cancer. Asian J Androl 18(4):530-2, 2016. PMID: 27034017.
- Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World J Clin Oncol 6(6):299-311, 2015. PMID: 26677444.
- Pilie P, Werbel WA, Riddell J, Shu X, Schaubel D, Gregg KS. Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transpl Infect Dis 17(4):551-7, 2015. e-Pub 2015. PMID: 26059180.
- Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat 132(2):487-98, 2012. e-Pub 2011. PMID: 21647677.
- Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF, Wulfkuhle JD, Liotta LA, Lem S, Baker JC, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL. Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev 20(3):476-82, 2011. e-Pub 2011. PMID: 21242333.
- Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 18(3):901-14, 2009. e-Pub 2009. PMID: 19258476.
- Baker JC, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev 17(8):1884-90, 2008. PMID: 18708376.
- Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 13(22 Pt 1):6834-41, 2007. PMID: 18006786.
Book Chapters
- Pilie PG, Jonasch E. Hereditary Renal Cell Carcinoma. In: Rare Kidney Tumors: Comprehensive Multidisciplinary Management and Emerging Therapies. Springer, Cham, 2019.
- Pilie PG. Death Receptors and Apoptosis; Cell-cycle Regulation; Tp53; RB1; CDKN2A regulation. In: Handbook of Targeted Cancer Therapy and Immunotherapy. Wolters Kluwer, Lippincott Williams & Wilkins: Netherlands, 2018.
- Pilie PG, Milliron K, Merajver S. DCIS and Hereditary Susceptibility for Breast Cancer. In: Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer. Springer Science & Business Media: New York, NY, 2015.
Grant & Contract Support
| Title: | Prostate SPORE Pilot Project |
| Funding Source: | University of Michigan |
| Role: | Co-Principal Investigator |
| Title: | Loan Repayment Program Grant for Clinical Research |
| Funding Source: | NIH |
| Role: | Trainee |
| Title: | Rational Combinations to Target the Replication Stress Response in Prostate Cancer |
| Funding Source: | Prostate Cancer Foundation - Young Investigator Award |
| Role: | Principal Investigator |
| Title: | Targeting the Replication Stress Response to Induce Anti-Cancer Immunity in Advanced Solid Malignancies |
| Funding Source: | Conquer Cancer Foundation - CDA |
| Role: | Principal Investigator |